Emerging clinical trials targeting the CD47-SIRPα axis have shown enhanced macrophage-mediated phagocytosis and tumor clearance, particularly when combined with checkpoint inhibitors or chemotherapy (62, 63). This evidence concerns the gene SIRPA and neoplasm.